Association between use of antiepileptic drugs and fracture risk: A systematic review and meta-analysis

Bone

Volumn 64, Issue , 2014, Pages 246-253

  Shen, Chunhong ^a   Chen, Feng ^b   Zhang, Yinxi ^a   Guo, Yi ^a   Ding, Meiping ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Ningbo Lihuili Hospital (Ningbo Medical Centre)   (China)

Author keywords

Antiepileptic drugs; Fracture risk; Meta analysis

Indexed keywords

ANTICONVULSIVE AGENT; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE;

ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; FRACTURE; HUMAN; MONOTHERAPY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; META ANALYSIS;

ANTICONVULSANTS; FRACTURES, BONE; HUMANS;

EID: 84899809603     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.018     Document Type: Article

References (50)

1. Reynolds E.H. Introduction: epilepsy in the world. Epilepsia 2002, 43:1-3.
2. Landmark C.J. Antiepileptic drugs in non-epilepsy disorders. CNS Drugs 2008, 22(1):27-47.
3. Johannessen Landmark C., Fossmark H., Larsson P.G., et al. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011, 95(1):51-59.
4. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. N Engl J Med 1995, 332(12):767-774.
5. Perreault S., Dragomir A., Blais L., et al. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Saf 2008, 17(3):248-259.
6. Ahmad B.S., Hill K.D., O'Brien T.J., et al. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology 2012, 79(2):145-151.
7. Jetté N., Lix L.M., Metge C.J., et al. Association of antiepileptic drugs with non-traumatic fractures: a population-based analysis. Arch Neurol 2011, 68(1):107.
8. Nicholas J.M., Ridsdale L., Richardson M.P., et al. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the General Practice Research Database. Seizure 2013, 22(1):37-42.
9. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
10. Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta-analysis. Acta Neurol Scand 2005, 112:277-286.
11. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000, 283:2008-2012.
12. Wells G., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2010, Ottawa Health Research Institute.
13. Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
14. Higgins J.P.T., Thompson S.G., Deeks J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
15. Reyes C., Formiga F., Coderch M., et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 2013, 52(2):557-561.
16. Lapi F., Simonetti M., Michieli R., et al. Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 2012, 50:85-90.
17. Tsiropoulos L., Andersen M., Nymark T., Lauritsen J., Gaist D., Hallas J. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008, 49(12):2092-2099.
18. Spector W., Shaffer T., Potter D.E.B., Correa-de-Araujo R., Limcangco M.R. Risk factors associated with the occurrence of fractures in U.S. nursing homes: resident and facility characteristics and prescription medications. J Am Geriatr Soc 2007, 55:327-333.
19. Souverein P.C., Webb D.J., Weil J.G., Van Staa T.P., Egberts A.C.G. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006, 66:1318-1324.
20. Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of β-blockers and risk of fractures. JAMA 2004, 292:1326-1332.
21. Van Staa T.P., Leufkens H.G.M., Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002, 31:508-514.
22. Leonard H., Downs J., Jian L., et al. Valproate and risk of fracture in Rett syndrome. Arch Dis Child 2010, 95:444-448.
23. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45(11):1330-1337.
24. Carbone L.D., Johnson K.C., Robbins C., et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the Women's Health Initiative (WHI). J Bone Miner Res 2010, 25(4):873-881.
25. Mezuk B., Morden N.E., Ganoczy D., Post E.P., Kilbourne A.M. Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration. Am J Geriatr Psychiatry 2010, 18:245-255.
26. Ensrud K.E., Blackwell T., Mangione C.M., et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949-957.
27. Vestergaard P., Tigaran S., Rejnmark L., Tigaran C., Dam M., Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999, 99:269-275.
28. Schelleman H., Pollard J.R., Newcomb C., et al. Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures. Pharmacoepidemiol Drug Saf 2011, 20(6):619-625.
29. Persson H.B.I., Alberts K.A., Farahmand B.Y., Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002, 43(7):768-772.
30. Watson K.C., Lentz M.J., Cain K.C. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues 2006, 16(6):346-352.
31. Bohannon A.D., Hanlon J.T., Landerman R., et al. Association of race and other potential risk factors with nonvertebral fractures in community-dwelling elderly women. Am J Epidemiol 1999, 149(11):1002-1009.
32. Rockville Bone health and osteoporosis: a report of the surgeon general 2004, US Department of Health and Human Services.
33. Brauer C.A., Coca-Perraillon M., Cutler D.M., Rosen A.B. Incidence and mortality of hip fractures in the United States. JAMA 2009, 302:1573-1579.
34. Alvarez-Nebreda M.L., Jiménez A.B., Rodríguez P., Serra J.A. Epidemiology of hip fracture in the elderly in Spain. Bone 2008, 42:278-285.
35. Lee R.H., Lyles K.W., Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010, 8:34-46.
36. Beerhorst K., van der Kruijs S.J.M., Verschuure P., Tan I.Y., Aldenkamp A.P. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci 2013, 331(1):19-25.
37. Nakken K.O., Taubøll E. Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 2010, 9(4):561-571.
38. Feldkamp J., Becker A., Witte O.W., et al. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000, 108:37-43.
39. Perucca P., Gilliam F.G. Adverse eff ects of antiepileptic drugs. Lancet Neurol 2012, 11:792-802.
40. Shorr R.I. Review: psychotropic drugs increase the risk of falls in older people. Evid Based Ment Health 1999, 2:95.
41. Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004, 5:S3-S15.
42. Pack A.M., Olarte L.S., Morrell M.J., Flaster E., Resor S.R., Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003, 4:169-174.
43. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
44. Boluk A., Guzelipek M., Savli H., Temel I., Ozişik H.I., Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004, 50:93-97.
45. Rasmussen H., Tenenhouse A. Thyrocalcitonin, osteoporosis and osteolysis. Am J Med 1967, 43:711-726.
46. Kim S.H., Lee J.W., Choi K.G., Chung H.W., Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007, 10:291-295.
47. Sheth R.D., Hermann B.P. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 2007, 37:250-254.
48. Zhang J., Wang K.X., Wie Y., et al. Effect of topiramate and carbamazepine on bone metabolism in children with epilepsy. Chin J Contemp Paediatr 2010, 12:96-98.
49. Koo D.L., Joo E.Y., Kim D., et al. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 2013, 104:134-139.
50. Phabphal K., Geater A., Limapichat K., Sathirapanya P., Setthawatcharawanich S., Leelawattana R. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. Epilepsia 2013, 54(6):e94-e98.